Brain gangliosides of a transgenic mouse model of Alzheimer's disease with deficiency in GD3-synthase: expression of elevated levels of a cholinergic-specific ganglioside, GT1α

Toshio Ariga*, Yutaka Itokazu*, Michael P. McDonald†, Yoshio Hirabayashi‡, Susumu Ando§ and Robert K. Yu*1

*Institute of Molecular Medicine and Genetics and Institute of Neuroscience, Medical College of Georgia, Georgia Regents University, Augusta, GA 30912, and VA Medical Center, Augusta, GA 30904, U.S.A.
†Departments of Neurology and Anatomy and Neurobiology, University of Tennessee Health Sciences Center, Memphis, TN, U.S.A.
‡Laboratory for Molecular Neuroscience, Brain Science Institute, Saitama, Japan
§Department of Biochemistry, The Tokyo Metropolitan Institute of Gerontology, Itabashi-ku, Tokyo, Japan

Cite this article as: Ariga T, Itokazu Y, McDonald MP, Hirabayashi Y, Ando S, Yu RK (2013) Brain gangliosides of a transgenic mouse model of Alzheimer's disease with deficiency in GD3-synthase: expression of elevated levels of a cholinergic-specific ganglioside, GT1α. ASN NEURO 5(2):art:e00113.doi:10.1042/AN20130006

ABSTRACT

In order to examine the potential involvement of gangliosides in AD (Alzheimer’s disease), we compared the ganglioside compositions of the brains of a double-transgenic (Tg) mouse model [APP (amyloid precursor protein)/PSEN1 (presenilin)] of AD and a triple mutant mouse model with an additional deletion of the GD3S (GD3-synthase) gene (APP/PSEN1/GD3S−/−). These animals were chosen since it was previously reported that APP/PSEN1/GD3S−/− triple-mutant mice performed as well as WT (wild-type) control and GD3S−/− mice on a number of reference memory tasks. Cholinergic neuron-specific gangliosides, such as GT1α and GQ1α, were elevated in the brains of double-Tg mice (APP/PSEN1), as compared with those of WT mice. Remarkably, in the triple mutant mouse brains (APP/PSEN1/GD3S−/−), the concentration of GT1α was elevated and as expected there was no expression of GQ1α. On the other hand, the level of c-series gangliosides, including GT3, was significantly reduced in the double-Tg mouse brain as compared with the WT. Thus, the disruption of the gene of a specific ganglioside-synthase, GD3S, altered the expression of cholinergic neuron-specific gangliosides. Our data thus suggest the intriguing possibility that the elevated cholinergic-specific ganglioside, GT1α, in the triple mutant mouse brains (APP/PSEN1/GD3S−/−) may contribute to the memory retention in these mice.

Key words: Alzheimer’s disease, amyloid β protein, Chol-1α ganglioside, transgenic mouse

INTRODUCTION

Gangliosides are sialic acid-containing GSLs (glycosphingolipids) expressed primarily, but not exclusively, in the outer leaflet of the plasma membrane of cells of all vertebrates [gangliosides are abbreviated using the nomenclature rules of IUPAC-IUB (1977) and according to Svennerholm (1963)]. Those GSLs are particularly abundant in the nervous system. Ganglioside metabolism is closely associated with brain development, and in some cases with the pathology of neurodegenerative diseases such as AD (Alzheimer’s disease). AD is the most common type of dementia with clinical symptoms that include deficits in memory, judgment, thinking and...
behaviour. The accumulation of Aβs (amyloid β-proteins) is one of the major pathological hallmarks in AD. Although the functions of gangliosides in the pathogenic mechanisms of AD are not completely understood, evidence has accumulated to indicate a critical role for gangliosides in binding to and aggregation of Aβs, the toxic peptides in AD brain. Thus, gangliosides are frequently used as biomarkers associated with the pathological events of AD (Ariga et al., 2011; Yanagisawa, 2011).

We recently examined the ganglioside composition of the brains of a double-Tg (transgenic) mouse model [APP (amyloid precursor protein)/PSEN1 (presenilin-1)] of AD that co-expresses mouse/human chimeric APP with the Swedish double-mutation and human PSEN1 with a deletion of exon 9 (Ariga et al., 2010). Although the accumulation of Aβ was confirmed in the double-Tg mouse brains and sera, the content and composition of the major ganglio-N-tetraosyl-series gangliosides in the brains were not significantly different between the double-Tg mice and WT (wild-type) mice (Ariga et al., 2010). This latter finding was in line with that reported by Sawamura et al. (2000), who also did not detect any changes in the major ganglioside patterns in the mutant PSEN2 double-Tg mice as compared with those in WT mice. The most interesting finding of our previous study was the increased expression of the Chol-1 antigens, GT1ax and GQ1bx, especially GQ1bx, in the brains of double-Tg (APP/PSEN1) mice as compared with those in WT mice.

A2B5 antigens, including the c-series gangliosides such as GT3, GT1c and GQ1c, are well-known marker molecules of glial precursor cells, O-2A progenitor cells, which differentiate into type-2 astrocytes and oligodendrocytes (Raff et al., 1983; Zhang, 2001). GT3 was detected in the developing embryonic mouse brains using A2B5 mAb (monoclonal antibody) and the expression of GT3 was significantly diminished during later development (Nagakute et al., 2007).

In a previous study, we established the triple-Tg mouse model of AD (APPswe/PSEN1/GD3S−/−) by crossing the breeding of the triple-Tg (APP/PSEN1) mouse model of AD with GD3S−/− mice (Bernardo et al., 2009). GD3S (GD3-synthase) is responsible for the biosynthesis of GD3, a key intermediate for the biosynthesis of b- and c-series gangliosides, including two of the major brain gangliosides: GD1b and GT1b. Surprisingly, Aβ plaques and the associated neuropathology were almost completely absent in the triple-Tg (APP/PSEN1/GD3S−/−) mice, resulting in cognitive improvement. These triple-Tg mice performed as well as WT controls on all behavioural tests of sensorimotor function, anxiety and cognition. We reasoned that there must be a correlation between the pathogenesis of AD and the unique ganglioside composition in the GD3S knockout animals. For this reason, we undertook a detailed analysis of the minor gangliosides, particularly GT1ax, GQ1bx and GT3, in the brain of the double-Tg and triple-Tg mice and found that these minor gangliosides were significantly altered. The elevated expression of GT1ax in the triple-Tg animals was particularly pronounced. Our data suggest that the elevated cholinergic-specific ganglioside, GT1ax, in the triple-mutant mouse brains (APP/PSEN1/GD3S−/−) may contribute to diminished plaque formation and, concomitantly, functional recovery in these mice.

MATERIALS AND METHODS

Gangliosides and antibodies
Chol-1α gangliosides, GQ1bx and GT1bx, were isolated from bovine brains (Ando et al., 1992; Hirabayashi et al., 1992). GD3 ganglioside was isolated from buttermilk (Ren et al., 1988). A mouse mAb, A2B5, was originally derived from a mouse immunized with 8-day chicken embryo retinas (Eisenbarth et al., 1979); the hybridoma cells were obtained from ATCC (Manassas). Mouse Chol-1α mAb (GGR-41) was obtained by immunizing mice with a GQ1bx-enriched ganglioside fraction extracted from bovine brain according to conventional procedures (Kusunoki et al., 1993).

Animals
The double-Tg mouse model of AD (APPswe/PSEN1) was purchased from the Jackson Laboratory (Bar Harbor; stock #004462) and propagated in our laboratories. The mice express the chimeric mouse/human APP gene harbouring the Swedish double-mutation (K595N/M596L) and a human PSEN1 gene with a deletion of exon 9. The triple-Tg mouse model of AD (APPswe/PSEN1) lacking the gene encoding GD3S (ST-II; ST8 α-N-acetylated neuraminidase, α-2,8-sialyltransferase 1; St8sia I) was prepared as previously described (Bernardo et al., 2009). All animals, both male and female, used for ganglioside analysis were from 7 to 9 months of age. The use of animals for this study was approved by the Institutional Animal Care and Use Committees at the Georgia Regents University and University of Tennessee Health Sciences Center.

Ganglioside isolation
Gangliosides were isolated from brain slices containing hippocampal/cortical tissue from WT, GD3S−/−, double-Tg and triple-Tg mice (n = 3 per group) as previously described (Yu and Ledeen, 1972) with some modifications (Ariga et al., 1988). Briefly, total lipids were extracted from brain tissues with 5 volumes each of chloroform–methanol (1:2, 1:1 and 2:1; v/v) and chloroform–methanol–water (30:60:8, v/v; Solvent A). Then, the combined extracts were evaporated and dissolved in 5 ml of Solvent A, and applied to a DEAE-Sephadex A-25 column (acetate form, 2-ml bed volume), followed by elution with 20 ml of solvent A to remove the neutral lipids. The acidic lipid fraction, containing gangliosides, was then eluted with 20 ml of chloroform–methanol–0.8 M
sodium acetate in water (30:60:8, v/v, Solvent B), followed by desalting using Sep-Pak Cartridge column chromatography (Waters Assoc.) (Kubo and Hoshi, 1985). The lipid-bound sialic acid ([NeuNAc (N-acetyleneuraminic acid or sialic acid)] content in the acidic lipid fraction was determined by the resorcinol–HCl reagent (Svennerholm, 1957). A portion of the acidic lipid fraction, equivalent to 1.5 μg of NeuNAc, was applied to an HPTLC (high-performance thin-layer chromatography) plate and developed with the solvent system of chloroform–methanol–water containing 0.2 % CaCl₂ · H₂O (50:45:10, v/v). Ganglioside bands were visualized by spraying with the resorcinol–HCl reagent followed by heating at 100°C.

**HPTLC-immunostaining using anti-Chol-1α and A2B5 mAb**

After developing the HPTLC plate described above, the plate was coated in a solution of n-hexane containing 0.4% (w/v) polyisobutylmethacrylate (Sigma Co.) for 1 min. After drying, the plate was incubated with anti-Chol-1α mAb [GGR-41;
IgG (immunoglobulin G) or A2BS mAb (IgM) diluted with 1 % (w/v) BSA in PBS at 4 °C overnight. The plate was then incubated with an HRP (horse radish peroxidase)-conjugated IgG or IgM secondary antibody (Jackson ImmunoResearch) diluted with 1 % (w/v) BSA in PBS for 1 h. Bands were detected using the Western Lightning Western blot chemiluminescence reagent (Perkin Elmer Life and Analytical Sciences). After the plate was dipped in chloroform to remove excess polymer, ganglioside bands were visualized by spraying with the orcinol–sulfuric acid reagent at 100 °C.

RESULTS AND DISCUSSION

GD3-synthase (STII; GD3S) is responsible for catalysing the biosynthesis of GD3, a key intermediate for the synthesis of other b- and c-series gangliosides (Figure 1). In GD3S gene knockout mice, all b-series gangliosides, including GD3, GD2, GD1b, GT1b and GQ1b, are deleted, and a-series gangliosides such as GM1, GD1a and GM2 show accretion (Okada et al., 2002). Chol-1α gangliosides are normally minor species in the brain and serve as unique markers of cholinergic neurons (Ando et al., 1992; Hirabayashi et al., 1992). They have also been shown immunocytochemically in human central nervous system (Obrocki and Borroni, 1988; Whittaker et al., 1992) and may find applications in human neuropathology. The expression of Chol-1α gangliosides in rat brain regions such as the hippocampus is developmentally regulated, and their concentrations increase with aging (Derrington and Borroni, 1990). Ando et al. (2004) further showed that treatment of anti-Chol-1α mAb inhibited the release of acetylcholine from synapto-somes. Interestingly, the memory and learning abilities of rats given anti-Chol-1α mAb were remarkably suppressed. On the contrary, treatment of Chol-1α gangliosides of the synaptosomal preparation induced choline uptake and enhanced acetylcholine synthesis. Thus, Chol-1α gangliosides may participate in maintaining cognitive functions such as memory and learning. In addition, Chol-1α gangliosides were shown to alleviate the decreased synaptic functions of aged brains (Ando et al., 1998). These findings suggest that Chol-1α antigens may play an important role in cholinergic synaptic transmission and participate in cognitive function. In our current study, we confirmed the expression of Chol-1α antigens in GD3S−/− mice (Figure 2A, lane 2). As expected, there was no expression of GQ1bα in the brain of GD3S−/− mice, but the levels of GT1αα were significantly elevated (Figure 2A, lane 2). In contrast, the concentrations of both Chol-1α ganglioside, GQ1bα and GT1αα, were increased in the brains of double-Tg mice as compared with those in the brains of WT mice, as shown in Figure 3(B), lane 2 and 3(C).

The APP/PSEN1/GD3S−/−−/− triple-mutant mice lack b-series gangliosides, which was compensated by a corresponding increase in the a-series gangliosides, GM1 (63.8 %) and GD1a (50.8 %), as compared with those of WT mice (Bernardo et al., 2009). In the present study, we found that the triple-mutant (APP/PSEN1/GD3S−/−−/−) mice expressed GT1αα, but not GQ1bα; the lack of GQ1bα was clearly because of the deletion of the GD3S gene (Figure 3C). Remarkably, we found that deletion of the gene encoding GD3S actually resulted in a significant overexpression of GT1αα ganglioside (Figures 2 and 3).

Another interesting aspect of the ganglioside composition in the brains of double-mutant (APP/PSEN1) and triple-mutant (APP/PSEN1/GD3S−/−−/−) mice was the expression of the c-series gangliosides. It is known that mouse mAb A2BS recognizes the c-series gangliosides (GQ1c, GT1c, GT3, etc.)
GT1α in triple-Tg AD mouse brains

Figure 3 HPTLC analysis of ganglioside expression in the brains of double-mutant, triple-mutant and WT mice
Gangliosides were separated by HPTLC using the solvent system of chloroform/methanol/(0.2% CuCl₂, 50:45:10, v/v) and bands were visualized by staining with the resorcinol-HCl reagent (A) or immunostaining with anti-Chol-1α mAb (GGR-41) (B). Each lane (1–3) contained 3 μg of lipid-bound sialic acid except lane 4. Lane 1, gangliosides of the brain of WT mice; lane 2, gangliosides of the brain of double-mutant mice; lane 3, gangliosides of the brain of triple-mutant mice; 4, authentic GT1α (20 ng) and GQ1β (20 ng), respectively. Please note that in lane 4, the amount of the two standards was too low to be revealed by the resorcinol-HCl reagent. (C) The concentrations of GT1α and GQ1β, present in the total gangliosides in each sample, were estimated by densitometric analysis of (B) (n = 3). In triple-Tg mice, the concentration of GT1α was significantly elevated compared with those in the WT and double-mutant mice. No detectable amounts of GQ1β was present in the triple-mutant mouse brains.

(Bieberich et al., 2001; Yu et al., 2004). c-Series gangliosides are normally present in very low abundance in adult brain, but are robustly expressed in embryonic brain (Yu et al., 2004); during brain maturation the biosynthesis of gangliosides is switched from the c- to the a- and b-series gangliosides (Yu et al., 2004). For this reason, A2B5 immunoreactivity has been widely used as an indicator of immature neurons and glia. In contrast with the Chol-1α antigens, a c-series ganglioside, GT3, was significantly reduced in double-mutant (APP/PSEN1) mouse brains as compared with that in WT mouse brains (Figure 4). This finding is different from previous immunohistochemical results found in human AD brains (Takahashi et al., 1991; Tooyama et al., 1992) in which A2B5-positive antigens were found to be increased in AD brain. This discrepancy may be owing to the specificity of the mAb A2B5, which has been reported to cross-react with sulfatide in AD brains (Majocha et al., 1989). It is possible that the immunoreactivity of the mAb A2B5 used in their study could arise not only from c-series ganglioside, but also from sulfatide, resulting in an overestimation of the immunohistochemical intensity.

Recent advances on the disruption of genes encoding glycosyltransferases for ganglioside biosynthesis have facilitated studies on the functional role of these glycolipids in...
the pathogenesis of many neurodegenerative diseases (Yu et al., 2012). In AD studies, Okawa et al. (2009) established Tg mice expressing human APP having Swedish and London mutations with GM2-synthase knockout mice. The mutant mice did not express GM1, GD1a, GD1b and GT1b, but robustly expressed GM3 and GD3, as reported by Takamiya et al. (1996). The mutant mice also showed a significant increase of Aβ accumulation in vascular tissues and formation of a severe dysphonic form of amyloid angiopathy in the brain. Most recently, Wu et al. (2011) reported that in mutant mice with a disrupted gene encoding GalNACT, α-synuclein expression was significantly elevated in the substantia nigra pars compacta of the brains. These mice showed overt motor disability on aging, loss of dopaminergic neurons and aggregation of α-synuclein, resulting in Parkinson-like symptoms.

On the other hand, Okada et al. (2002) established a GD3S gene knockout mouse in which all b-series gangliosides were deleted. Interestingly, these mice showed no morphological changes in the brains and apparent abnormal behaviour. Moreover, no differences in Fas-mediated apoptotic reaction in lymphocytes compared with the WT mice were found. However, the mutant mice exhibited reduced regeneration of axotomized hypoglossal nerves compared with the WT mice, suggesting that b-series gangliosides are more important in the repair of damaged nerves than in the differentiation of the nervous system. In our previous study, we (Bernardo et al., 2009) established the triple-mutant mouse model of AD (APP/PSEN1/GD3S−/−) in which all b-series gangliosides, including GD3, were absent, but GM1 and GD1a were significantly increased. Interestingly, Aβ plaques and the
associated neuropathology were almost completely absent in the triple-mutant mice, which showed no impairment of cognitive functions. These observations suggest that b-series gangliosides derived from the action of GD3S are one of the major causes of Aβ accumulation and AD. Analysis of these triple-mutant mice may contribute to our understanding of the neurobiological and behavioural characteristics of Aβ-ganglioside interaction as an essential step toward elucidating the early pathological events in AD. Thus, inhibition of GD3S may be a useful therapeutic target to restore the cognitive deficits, amyloid plaque formation, and neurodegeneration observed in AD (Bernardo et al., 2009). Several investigators have described aberrant ganglioside metabolism may be participated in the pathogenesis in AD (for review, see Ariga et al., 2011). In this regard, it is interesting to note that chronic infusion of GM1 into the lateral ventricle of patients with AD for 1 year resulted in remarkable improvement of their memory function (Svennerholm et al., 2002). The underlying mechanism of the GM1-induced effect is a subject of considerable speculation. Nonetheless, an increased level of GM1 in the triple mutant mice is consistent with the above observation and may also contribute to the observed improved cognitive improvement in these mice.

In conclusion, Chol-1α antigens and A285-positive c-series gangliosides are normally found as minor components in mouse brains and their expression is developmentally regulated (Ngamukote et al., 2007). At present, the functional role of those gangliosides, especially Chol-1α, in the pathogenesis of AD is still unknown. Our current findings that those gangliosides are overexpressed in the triple Tg model of AD, which also exhibits improved memory function and no amyloid formation, could provide some important directions for future research.

FUNDING

This work was supported, in part, by a VA Merit Award [grant number 1 IO1BX001388 (to R.K.Y.)] and the National Institutes of Health (NIH) [grant numbers RO1 NS26994 and RO1 NS11853 (to R.K.Y.) and RO1 AG031253 and R21 AG041935 (to M.P.M.)].

REFERENCES

Ando S, Hirabayashi Y, Kon K, Inagaki F, Tate S, Whittaker VP (1992) A trisialoganglioside containing a sialyl alpha 2-6 N-acetylgalactosamine residue is a cholinergic-specific antigen, Chol-1 alpha. J Biochem 111:287–290.
Ando S, Tanaka Y, Kobayashi S, Fukui F, Iwamoto M, Waki H, Tai T, Hirabayashi Y (2004) Synthetic function of cholinergic-specific Chol-1 alpha ganglioside. Neurochem Res 29:857–867.
Ando S, Tanaka Y, Waki H, Kon K, Iwamoto M, Fukui F (1998) Gangliosides and sialylcholesterol as modulators of synaptic functions. Ann N Y Acad Sci 845:232–239.

Ariga T, Macala LJ, Saito M, Margolis RK, Greene LA, Margolis RU, Yu RK (1988) Lipid composition of PC12 pheochromocytoma cells: characterization of globoside as a major neutral glycolipid. Biochemistry 27:52–58.
Ariga T, Wakade C, Yu RK (2011) The pathological roles of ganglioside metabolism in Alzheimer’s disease: effects of gangliosides on neurogenesis. Int J Alzheimers Dis 2011:193618.
Ariga T, Yanagisawa M, Wakade C, Ando S, Buccioncufo JJ, McDonald MP, Yu RK (2010) Ganglioside metabolism in a transgenic mouse model of Alzheimer’s disease: expression of Chol-1 alpha antigens in the brain. ASN NEURO 2:art:e00044.doi:10.1042/AN20100002.
Bernardo A, Harrison FE, McCord M, Zhao J, Bruchey A, Davies SS, Jackson Roberts 2nd L, Mathews PM, Matsuoka Y, Ariga T, Yu RK, Thompson R, McDonald MP (2009) Elimination of GD3 synthase improves memory and reduces amyloid-beta plaque load in transgenic mice. Neurobiol Aging 30:1777–1791.
Bieberich E, MacKinnon S, Silva J, Yu RK (2001) Regulation of apoptosis during neuronal differentiation by ceramide and b-series complex gangliosides. J Biol Chem 276:44396–44404.
Derrington EA, Borroni E (1990) The developmental expression of the cholinergic-specific antigen Chol-1 in the central and peripheral nervous system of the rat. Brain Res Dev Brain Res 52:131–140.
Eisenbarth GS, Walsh FS, Nirenberg M (1979) Monoclonal antibody to a plasma membrane antigen of neurons. Proc Natl Acad Sci USA 76:4913–4917.
Hirabayashi Y, Nakao T, Irie F, Whittaker VP, Kon K, Ando S (1992) Structural characterization of a novel cholinergic neuron-specific ganglioside in bovine brain. J Biol Chem 267:12973–12978.
Kubo H, Hoshi M (1985) Elimination of silica gel from gangliosides by using a reversed-phase column after preparative thin-layer chromatography. J Lipid Res 26:638–641.
Kusunoki S, Chiba A, Hirabayashi Y, Irie F, Kotani M, Kawashima I, Tai T, Nagai Y (1993) Generation of a monomolecular antibody specific for a new class of minor ganglioside antigens, G010 alpha and GT1a alpha: its binding to dorsal and lateral horn of human thoracic cord. Brain Res 623:83–88.
Majocha RE, Jungalwala FB, Rodenys A, Marotta CA (1989) Monoclonal antibody to embryonic CNS antigen A285 provides evidence for the involvement of membrane components at sites of Alzheimer degeneration and detects sulfatides as well as gangliosides. J Neurochem 53:953–961.
Ngamukote S, Yanagisawa M, Ariga T, Ando S, Yu RK (2007) Developmental changes of glycosphingolipids and expression of glycosynes in mouse brains. J Neurochem 103:2327–2341.
Obock J, Borroni E (1988) Immunocytochemical evaluation of a cholinergic-specific ganglioside antigen (Chol-1) in the central nervous system of the rat. Exp Brain Res 72:71–82.
Okawa N, Yamaguchi H, Ogino K, Taki T, Yuyama K, Yamamoto N, Shin RW, Furukawa K, Yanagisawa K (2009) Gangliosides determine the amyloid pathology of Alzheimer’s disease. Neuroreport 20:1043–1046.
Okada M, Itoh Mi M, Haraguchi M, Okajima T, Inoue M, Dishi H, Matsuya Y, Iwamoto T, Kawano T, Fukumoto S, Miyazaki H, Furukawa K, Alizawa S (2002) B-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesions hypoglossal nerve. J Biol Chem 277:1633–1636.
Raff MC, Miller RH, Noble M (1983) A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303:390–396.
Ren S, Scardale JDN, Ariga T, Zhang Y, Klein RA, Hartmann R, Kushi Y, Egge H, Roberts 2nd L, Mathews PM, Matsuoka Y, Ariga T, Yu RK (2012) O-acylated gangliosides in bovine buttermilk. Characterization of 7-O-acetyl, 9-O-acetyl, and 7,9-di-O-acetyl GD3. J Biol Chem 275:26232–26238.
Sawamura N, Morishima-Kawashima M, Waki H, Kobayashi K, Kuruouchi T, Frosch MP, Ding K, Ito M, Kim TW, Tanzi RE, Oyama F, Tabira T, Ando S, Ichihara Y (2000) Mutant presenilin 2 transgenic mice. A large increase in amyloid production and plaque formation. Nature 403:396–399.
Oikawa N, Yamaguchi H, Ogino K, Taki T, Yuyama K, Yamamoto N, Shin RW, Furukawa K, Yanagisawa K (2009) Gangliosides determine the amyloid pathology of Alzheimer’s disease. Neuroreport 20:1043–1046.
Okada M, Itoh Mi M, Haraguchi M, Okajima T, Inoue M, Dishi H, Matsuya Y, Iwamoto T, Kawano T, Fukumoto S, Miyazaki H, Furukawa K, Alizawa S (2002) B-series Ganglioside deficiency exhibits no definite changes in the neurogenesis and the sensitivity to Fas-mediated apoptosis but impairs regeneration of the lesioned hypoglossal nerve. J Biol Chem 277:1633–1636.
Raff MC, Miller RH, Noble M (1983) A glial progenitor cell that develops in vitro into an astrocyte or an oligodendrocyte depending on culture medium. Nature 303:390–396.
Ren S, Scardale JDN, Ariga T, Zhang Y, Klein RA, Hartmann R, Kushi Y, Egge H, Yu RK (1992) O-acylated gangliosides in bovine buttermilk. Characterization of 7-O-acetyl, 9-O-acetyl, and 7,9-di-O-acetyl GD3. J Biol Chem 275:26232–26238.
Sawamura N, Morishima-Kawashima M, Waki H, Kobayashi K, Kuruouchi T, Frosch MP, Ding K, Ito M, Kim TW, Tanzi RE, Oyama F, Tabira T, Ando S, Ichihara Y (2000) Mutant presenilin 2 transgenic mice. A large increase in amyloid production and plaque formation. Nature 403:396–399.
Svennerholm L (1957) Quantitative estimation of sialic acids. II. A colorimetric resorcinol–hydrochloric acid method. Biochim Biophys Acta 24:604–611.
Svennerholm L (1963) Chromatographic Separation of Human Brain Gangliosides. J Neurochem 10:613–623.
Svennerholm L, Brane G, Karlsson I, Lekman A, Ramstrom I, Wikkelso C (2002) Alzheimer disease–effect of continuous intracerebroventricular treatment with GM1 ganglioside and a systematic activation programme. Dement Geriatr Cogn Disord 14:128–136.
Takahashi H, Hirokawa K, Ando S, Obata K (1991) Immunohistological study on brains of Alzheimer’s disease using antibodies to fetal antigens, C-series gangliosides and microtubule-associated protein S. Acta Neuropathol 81:626–631.
Takamiya K, Yamamoto A, Furukawa K, Yamashiro S, Shin M, Okada M, Fukumoto S, Haraguchi M, Takeda N, Fujimura K, Sakae M, Kishikawa M, Shiku H, Aizawa S (1996) Mice with disrupted GM2/GD2 synthase gene lack complex gangliosides but exhibit only subtle defects in their nervous system. Proc Natl Acad Sci USA 93:10662–10667.
The nomenclature of lipids. Recommendations (1976) IUPAC-IUB commission on biochemical nomenclature. Lipids 12:455–468.
Tooyama I, Yamada T, Kim SU, McGeer PL (1992) Immunohistochemical study of A2B5-positive ganglioside in postmortem human brain tissue of Alzheimer disease, amyotrophic lateral sclerosis, progressive supranuclear palsy and control cases. Neurosci Lett 136:91–94.
Whittaker VP, Derrington EA, Borroni E (1992) Chol–1 is a cholinergic marker in the human central nervous system. Neuroreport 3:341–344.
Wu G, Lu ZH, Kulkarni N, Amin R, Ledeen RW (2011) Mice lacking major brain gangliosides develop parkinsonism. Neurochem Res 36:1706–1714.
Yanagisawa K (2011) Pathological significance of ganglioside clusters in Alzheimer’s disease. J Neurochem 116:806–812.
Yu RK, Bieberich E, Xia T, Zeng G (2004) Regulation of ganglioside biosynthesis in the nervous system. J Lipid Res 45:783–793.
Yu RK, Ledeen RW (1972) Gangliosides of human, bovine, and rabbit plasma. J Lipid Res 13:680–686.
Yu RK, Tsai YT, Ariga T (2012) Functional roles of gangliosides in neurodevelopment: an overview of recent advances. Neurochem Res 37:1230–1244.
Zhang SC (2001) Defining glial cells during CNS development. Nat Rev Neurosci 2:840–843.